Future-Proofing Pharmacovigilance in an AI Era

By: Ana Pedro Jesuíno, Associate Director of Marketed Product Safety, IQVIA

Clinical research organizations (CROs) are entering an era in which pharmacovigilance systems are doing more than just tracking copious amounts of data. They must also keep pace with evolving regulations, manage the growing volume of adverse event reports, and respond to heightened scrutiny from both regulators and the public.

From a workforce perspective, however, the resources needed to meet these demands are stretched thin. To mitigate this issue, pharmaceutical companies should be shifting from resource-intensive business models to technology-driven strategies that optimize workflows, reduce manual effort, and enhance data accuracy. This growing need is driving leaders toward modern models that prioritize patient safety while improving operational efficiency. By embracing automation, advanced analytics, and integrated platforms, leaders can maintain patient safety while driving operational efficiency and scalability across their organizations.

AI and automation have become essential tools in this shift. Machine learning accelerates case processing by screening reports, detecting patterns, and flagging anomalies at a scale and speed beyond human capability. However, technology cannot shoulder these burdens alone. Oversight, judgment, and accountability remain inherently human responsibilities. This is where local qualified persons for pharmacovigilance (LQPPVs) play a critical role. By combining local expertise with advanced technologies, LQPPVs help CROs strengthen compliance, enhance patient safety, and future-proof their pharmacovigilance systems in ways that neither humans nor machines could achieve alone.

Why LQPPVs Matter

LQPPVs are the bridge between a company’s global operations and local regulatory authorities. They ensure that commercial pharmacovigilance systems remain compliant with the requirements of a specific country or region. Their job responsibilities can range from overseeing case management to monitoring literature and ensuring continual inspection readiness.

The role of an LQPPV has become more critical as regulations have become more stringent. For example, the European Medicines Agency and other regulators have updated their pharmacovigilance practice guidelines with a heightened emphasis on robust vendor oversight and accountability. Globalization further complicates compliance, requiring coordination across multiple jurisdictions, each with its own rules and cultural context. LQPPVs help organizations navigate these complexities with the local expertise necessary to protect patients and relieve pressure on central teams. They enable companies to:

• Ensure compliance efficiently across diverse regulatory landscapes.
• Scale operations quickly without the overhead of hiring and training local teams.
• Leverage technology-driven workflows that reduce manual effort and improve data quality.
• Maintain inspection readiness while focusing internal resources on strategic priorities.

Balancing Compliance and Operational Efficiency

Pharmacovigilance faces a dual challenge: ensuring rigorous compliance while remaining operationally sustainable. Safety monitoring requires continuous vigilance, yet companies cannot afford to dedicate unlimited resources to it. A McKinsey analysis of generative AI found that pharma could unlock $60 to $110 billion in annual value if the right foundations were in place. In the pharmacovigilance setting, this value will only be realized if humans remain in the technological loop to provide strong oversight.

LQPPVs can establish a balance between the needs of compliance and sustainability. They ensure that AI-enabled systems align with local expectations while applying human judgment to contextualize data. For example, AI may flag clusters of headache reports, but an LQPPV can understand whether those reports reflect cultural differences in reporting behavior or a true emerging safety signal. This mix of efficiency and nuance reduces manual burden without compromising accountability.

This combination enables CROs to reduce manual burden, accelerate compliance activities, and ensure accountability with a balance between regulatory rigor and operational efficiency that neither humans nor machines could achieve alone. By leveraging CROs, companies gain access to a network of skilled LQPPVs supported by advanced technologies and standardized processes.

The Benefits of Continuous Compliance

Oversight is not a one-time task. It must be continuous. The National Center for Biotechnology Information stresses the importance of rigorous validation, monitoring, and oversight in AI systems. In pharmacovigilance, this translates into ensuring that technology and processes remain aligned with evolving regulations at all times. Embedded within their local regulatory environments, LQPPVs are uniquely positioned to provide oversight at the regional level, serving as stewards of both technology and process.

By maintaining inspection readiness, LQPPVs relieve central teams from the constant fear of audit failure. Unlike temporary staffing solutions, LQPPVs are embedded in their regulatory environments, attuned to national guidelines, and skilled at preparing documentation that aligns with both global and local expectations. Their presence ensures that compliance is not episodic but sustained. This combination creates a proactive compliance framework that is efficient, resilient, and future-ready.

Efficiency Through AI and Expertise

Pharmacovigilance is inherently data-intensive, drawing on sources ranging from spontaneous reports to literature and the millions of social media users generating safety information. AI can process vast data streams, but as the FDA has made clear in its guidance on AI in drug development, accountability cannot be delegated to algorithms. The role of interpreting the results and making decisions that impact patients must be administered by real human experts to ensure safety.

This is where LQPPVs deliver strategic value. LQPPVs provide the critical human oversight needed to interpret AI outputs, apply local regulatory knowledge, and make informed safety decisions. The initial utilization of AI for data processing is acceptable because it allows PV teams to direct their attention to cases that require advanced decision-making. This division of labor alleviates mundane and manual workloads while preserving the integrity of safety decisions. It also reassures regulators that AI is being used responsibly under the careful supervision of qualified professionals.

From a vendor oversight perspective, LQPPVs can leverage their proximity to the day-to-day operations, which allows them to identify gaps, inconsistencies or risks in a vendor’s performance. This closeness also allows them to escalate issues more efficiently and ensure that corrective actions are taken before they become compliance failures.

Future-Proofing PV Systems

As AI and additional advances in technology continue to become deeply rooted within pharmacovigilance, the future of the industry will depend on its ability to maintain strong human oversight while balancing responsible AI integrations. Regulatory agencies like the FDA are already reviewing hundreds of AI-enabled submissions and are committed to developing frameworks for its safe and effective use. This signals a clear direction: technology will accelerate processes, but compliance and accountability remain human responsibilities.

Still, LQPPVs offer a proven way forward. The combination of local expertise with modern technology generates a foundation for companies to build customized systems that are based on compliance, efficiency, and adaptability. LQPPVs are the compass that can guide teams in ensuring that AI is applied responsibly, regulatory expectations are met, and patient safety remains at the center.

If applied correctly, organizations can shift from fragmented and disparate models to one that is unified and strategic. By leveraging a comprehensive and intelligent network of LQPPVs who anticipate changes, adapt processes, and provide continuous oversight, organizations can leave behind the scramble to meet new requirements and fear of audits. Today’s organizations have the opportunity to thrive in an era of dynamic compliance by transforming operational burdens into opportunities for continuous improvement.

Final Thoughts on LQPPVs

Pharmaceutical companies are under increasing pressure to keep pace with evolving regulations, global requirements, and floods of patient safety data. While AI and automation promise efficiency, technology still cannot replace the critical oversight required by pharmacovigilance.

LQPPVs bridge this gap. They strengthen vendor oversight, provide scalable resources, and ensure ethical AI integration. By relieving internal teams of burdensome tasks, they allow organizations to focus on high-value work and long-term strategy.

Futureproofing within pharmacovigilance will not be achieved by technology alone. Success will be predicated on combining the speed of AI with the accountability of human oversight anchored by the local expertise of LQPPVs. That is how the pharmacovigilance industry will meet its obligations, protect patients, and navigate an increasingly complex regulatory landscape with confidence.